Recent developments, however, suggest that strategies to treat pain are starting to match its complexity with a new ...

Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...

Despite advances, there remain gaps in the understanding of and personalized treatment for chronic pain in rheumatology, especially among women.

People undergoing hemodialysis treatment for kidney failure often experience chronic pain related to their condition, but it ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach and ...

Recent research has focused on evaluating the effectiveness of prolotherapy compared to other treatment modalities ... to better understand its role in pain management. Prolotherapy: A nonsurgical ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...

The industry is grappling with significant market shifts amidst emerging technologies and changing demands. Companies are now ...

South San Francisco, CA, January 30, 2025 – The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated to regenerative medicine, has awarded nearly ...

The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities ... anti-CD38 CAR-T therapy for the treatment of multiple myeloma ...

Treatment modalities pull from Cognitive Behavioral Therapy ... approach to managing chronic pain. We will share resources, learn stress and anger management techniques, discuss the impact ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatmentAlzheimer's disease progression does ...